BioAge Labs, Inc (BIOA)vsViatris Inc (VTRS)
BIOA
BioAge Labs, Inc
$5.94
0.00%
HEALTHCARE · Cap: $229.03M
VTRS
Viatris Inc
$18.77
+0.27%
HEALTHCARE · Cap: $21.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 142221% more annual revenue ($14.74B vs $10.36M). BIOA leads profitability with a 0.0% profit margin vs -2.8%. VTRS earns a higher WallStSmart Score of 48/100 (D+).
BIOA
Avoid31
out of 100
Grade: F
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIOA.
Margin of Safety
-82.5%
Fair Value
$8.84
Current Price
$18.77
$9.93 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
1.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BIOA
The strongest argument for BIOA centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : BIOA
The primary concerns for BIOA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
BIOA profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
BIOA carries more volatility with a beta of 1.08 — expect wider price swings.
VTRS is growing revenue faster at 4.9% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (48/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioAge Labs, Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?